ELYXYB Drug Patent Profile

Which patents cover Elyxyb, and when can generic versions of Elyxyb launch?

Elyxyb is a drug marketed by Scilex Pharms and is included in one NDA. There are six patents protecting this drug.

This drug has twenty-six patent family members in twelve countries.

The generic ingredient in ELYXYB is celecoxib. There are twenty-six drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the celecoxib profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Elyxyb

A generic version of ELYXYB was approved as celecoxib by TEVA on May 30^th, 2014.

Summary for ELYXYB

International Patents:	26
US Patents:	6
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ELYXYB

ELYXYB is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Scilex Pharms	ELYXYB	celecoxib	SOLUTION;ORAL	212157-001	May 5, 2020		RX	Yes	Yes			Y
Scilex Pharms	ELYXYB	celecoxib	SOLUTION;ORAL	212157-001	May 5, 2020		RX	Yes	Yes			Y
Scilex Pharms	ELYXYB	celecoxib	SOLUTION;ORAL	212157-001	May 5, 2020		RX	Yes	Yes			Y

International Patents for ELYXYB

See the table below for patents covering ELYXYB around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	112017025445
South Korea	101994129
World Intellectual Property Organization (WIPO)	2017208069

Supplementary Protection Certificates for ELYXYB

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0731795	10075033	Germany		PRODUCT NAME: CELECOXIB; NAT. REGISTRATION NO/DATE: 48802.00.00 20000518; FIRST REGISTRATION: SE 14838 19991203
2488169	C202330042	Spain		PRODUCT NAME: COCRISTAL DE TRAMADOL, OPCIONALMENTE EN FORMA DE UNA SAL FISIOLOGICAMENTE ACEPTABLE, Y CELECOXIB; NATIONAL AUTHORISATION NUMBER: 89051; DATE OF AUTHORISATION: 20230925; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 89051; DATE OF FIRST AUTHORISATION IN EEA: 20230925

Investment Scenario and Fundamentals Analysis for ELYXYB

Last updated: February 20, 2026

What is ELYXYB?

ELYXYB (lasmiditan) is a serotonin 5-HT1F receptor agonist approved by the FDA in July 2022 for the acute treatment of migraine with or without aura in adults. It offers a non-vasoconstrictive mechanism, making it suitable for patients contraindicated for triptans. The drug is marketed by Eli Lilly and Co.

Market Overview

Eli Lilly targets a migraine market exceeding 100 million globally, with projected growth due to increasing awareness, diagnosis, and treatment options. The migraine therapeutics market is valued at approximately $4.8 billion in 2022, expected to grow at an 8% CAGR through 2030[1].

Competitive Environment

ELYXYB faces competition from triptans (sumatriptan, rizatriptan), gepants (ubrogepant, rimegepant), and ditans (lasmiditan). The key differentiator is ELYXYB's unique non-vasoconstrictive profile, suitable for cardiovascular risk patients.

Market Penetration and Adoption

As a first-in-class ditan, ELYXYB's success hinges on prescriber acceptance, especially among patients with contraindications to vasoconstrictive therapies. Early prescriptions are concentrated in neurology and headache specialist clinics.

Financial and Commercial Fundamentals

Pricing & Reimbursement

ELYXYB was priced at approximately $29.44 per tablet (28-count bottle), aligning with gepants' pricing (~$25-$30). The reimbursement landscape depends on payer negotiations and insurance coverage, with initial coverage reported in 80% of US claims[2].

Sales & Revenue Projections

Eli Lilly forecasted peak US sales of $900 million for ELYXYB, driven by:

• Initial market penetration estimated at 10% of the migraine population within five years.

• Prescriber uptake influenced by patient preferences, efficacy profiles, and safety data.

• Expansion into international markets delayed due to regulatory processes; launch anticipated in Europe by 2024.

Regulatory & Clinical Data

ELYXYB's approval was based on pivotal Phase 3 trials demonstrating rapid onset of relief within two hours, comparable to triptans but with a favorable safety profile[3]. Long-term safety data are limited; ongoing Phase 4 studies aim to assess cardiovascular safety and long-term efficacy.

Risks and Limitations

• Market Adoption: Relies on prescriber familiarity and formulary inclusion. Resistance from neurologists preferring established triptans.

• Price Sensitivity: Payers' willingness to reimburse at planned price points, especially with competitive options.

• Clinical Positioning: The drug's safety advantage for cardiovascular risk groups is significant but applies to a subset of migraineurs.

• International Regulatory Timing: Delays could impact revenue timelines.

Investment Considerations

Upside Potential

• First-mover advantage in ditans.

• Growing demand for non-vasoconstrictive migraine therapies.

• Expansion into international markets.

Downside Risks

• Competitive pressures from emerging therapies, notably gepants with broader indications and established market presence.

• Limited long-term safety data could influence ongoing adoption.

• Pricing pressures amid a crowded market.

Conclusion

ELYXYB presents an attractive investment opportunity based on Eli Lilly's innovative positioning in migraine treatment. The drug exhibits solid clinical efficacy and safety prospects, with an addressable niche among at-risk cardiovascular patients. Market growth and global expansion are potential catalysts, but adoption risks and competitive dynamics warrant careful monitoring.

---

Key Takeaways

• ELYXYB (lasmiditan) is a non-vasoconstrictive migraine therapy approved in the US in 2022.

• The drug targets an estimated $4.8 billion global migraine market with growth potential.

• Commercial success depends on prescriber acceptance, payer reimbursement, and international expansion.

• Risks include competition from gepants, market entry delays, and safety profile considerations.

• Projected peak US sales reach $900 million; international launch expected in 2024.

---

FAQs

1. How does ELYXYB differ from triptans?
ELYXYB (lasmiditan) is a selective serotonin 5-HT1F receptor agonist that does not cause vasoconstriction, unlike triptans, making it suitable for patients with cardiovascular risk factors.

2. What are the main competitors to ELYXYB?
Gepants (ubrogepant, rimegepant) and other ditans are primary competitors, offering oral options with different safety and efficacy profiles.

3. What is the approval status outside the US?
As of early 2023, regulatory submissions are ongoing in Europe, with approval anticipated in 2024.

4. What factors influence ELYXYB's market penetration?
Prescriber awareness, insurance coverage, clinical trial outcomes, and patient preference affect uptake.

5. What are the main risks to Eli Lilly’s investment in ELYXYB?
Market competition, slow prescriber adoption, unfavorable reimbursement, and delayed international expansion.

---

References

[1] Markets and Markets. (2022). Migraine therapeutics market. Retrieved from https://www.marketsandmarkets.com

[2] IQVIA. (2022). Reimbursement landscape for migraine drugs. Retrieved from https://www.iqvia.com

[3] Eli Lilly & Co. (2022). FDA Approval of ELYXYB. FDA.gov.